A new report highlighting the UK's top female talent in the pharma and biotech sectors shows seven of the 50 women profiled are based at Stevenage Bioscience Catalyst (SBC) in Hertfordshire. The report, entitled '50 Movers & Shakers in BioBusiness 2019', was published by BioBeat on 6 November and features Hertfordshire LEP Board Member and SBC CEO Dr Sally Ann Forsyth.
The report focuses on the impact of individuals across five key areas, namely science, finance, collaboration, patient impact and infrastructure. The SBC-based individuals span these segments and include:
- Dr Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst
- Veronique Bouchet, Chief Medical Officer, RowAnalytics and SBC Board member
- Melanie Lee, CEO, LifeArc
- Jane Whitrow, VP Business Operations, Freeline Therapeutics
- Pauline Stasiak, Investment Principal, LifeArc Seed Fund
- Jane Robertson, Chief Medical Ofﬁcer, Achilles Therapeutics
- Anna Outhwaite, Head, ATTC Network Coordination, Cell and Gene Therapy Catapult
The 50 Movers and Shakers report has been released in advance of the 'BioBeat19 Summit: Accelerating Cell and Gene Therapy', which will be hosted by GSK and SBC on Tuesday 19 November 2019. Emma Walmsley, CEO at GSK will deliver the keynote address, followed by discussions with leading women from across the cell and gene therapy landscape examining the journey from science to patients, and the value of these transformational therapies.
Dr Sally Ann Forsyth, CEO at Stevenage Bioscience Catalyst, said: “It is an honour to be included amongst this list of exceptional women from across the sector. We are proud that SBC is home to so many of this year’s Movers and Shakers. I look forward to further showcasing our talents when we co-host the BioBeat19 event later this month.”
Stevenage Bioscience Catalyst is a world-leading science park of global significance and home to the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, it has attracted over 40 high-profile occupier businesses and world-class research organisations to Stevenage.
This includes the Cell and Gene Therapy Catapult Manufacturing Centre which is currently undergoing expansion to support up to 12 cell and gene therapy companies, towards which Hertfordshire LEP has invested £2.9m from the Local Growth Fund. Occupiers of the SBC campus have raised almost £1bn of investment, of which around 60% has been invested into cell and gene therapy companies.